Gilder Gagnon Howe & CO LLC Biocryst Pharmaceuticals Inc Transaction History

Gilder Gagnon Howe & CO LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $16,346 - $22,437	-1,515 Reduced 0.5%	303,642 $3.83 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $267,092 - $605,273	-33,852 Reduced 9.99%	305,157 $3.23 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $20,461 - $34,975	-1,770 Reduced 0.52%	339,009 $5.51 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $301,558 - $417,002	26,973 Added 8.6%	340,779 $4.72 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $5,868 - $7,289	413 Added 0.13%	313,806 $4.51 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $968,867 - $1.76 Million	101,986 Added 48.24%	313,393 $4.96 Million
Q1 2021 May 17, 2021	BUY	$7.37 - $13.61 $1.56 Million - $2.88 Million	211,407 New	211,407 $2.15 Million
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $2 Million - $5.1 Million	-592,200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $2.03 Million - $3.27 Million	592,200 New	592,200 $2.03 Million

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.